AKASA

AKASA is rapidly becoming the GenAI partner of choice for leading health systems, with recent national recognition of our Cleveland Clinic deployment as “one of the most comprehensive real-world uses of GenAI in healthcare finance to date.” Across customers, AKASA now delivers an average of $3.1M in additional revenue and 4,270 additional quality indicators per 10,000 discharges, demonstrating consistent, measurable impact.

Our advantage comes from building a custom LLM for each health system, capturing their clinical nuance to drive superior accuracy across the mid-cycle — spanning prior authorization, CDI, inpatient coding, and clinical denials appeals.

This approach allows organizations to modernize critical workflows and unlock material improvements in both revenue and quality.

With investors including Andreessen Horowitz, BOND, Costanoa Ventures, and others, we’ve raised more than $200M to help eliminate the financial complexity of healthcare. We’re rebuilding the revenue cycle with AI. Let’s chat.